Pemvidutide
Also called ALT-801
Subcutaneous (under the skin)Human study reference
Research reference
Human study
MOMENTUM phase 2 trial
Once weekly; separate 1.2, 1.8 and 2.4 mg study groups
48 weeks
MOMENTUM investigator abstract, ADA (2024) ↗When results may show
- When change was measured
- Weight was measured over 48 weeks. The source is an investigator conference abstract, not a full methods paper.
- When to assess
- 48 weeks
- Conditions and limitations
- 391 adults with overweight plus a related condition or obesity. A target group is not a starter escalation. No complete titration, mixing volume or personal stopping rule is inferred from this abstract.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Vial arithmetic
Published research contexts for Pemvidutide describe 1.2–2.4 mg per administration. Descriptive only, not a recommendation.
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 1.57× single dose
- Time to steady state
- 25.0days
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- MOMENTUM investigator abstract, ADA (2024)A target group is not a starter escalation. No complete titration, mixing volume or personal stopping rule is inferred from this abstract.
Next steps
Pemvidutide beginner guideOpen Pemvidutide planning worksheetEstimate Pemvidutide vial costTrack Pemvidutide notes